Vitamin D, Hypertension, Left Ventricular Hypertrophy, and Diastolic Dysfunction

Current Cardiovascular Risk Reports

Volumn 5, Issue 4, 2011, Pages 314-322

  Nigwekar, Sagar U ^a   Bhan, Ishir ^a   Thadhani, Ravi ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Diastolic blood pressure; Hypertension; Left ventricular hypertrophy; Systolic blood pressure; Vitamin D

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCITRIOL; CALCIUM CARBONATE; COLECALCIFEROL; PARICALCITOL; PLACEBO; VITAMIN D;

BLOOD PRESSURE MONITORING; CARDIOMEGALY; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; HYPERTENSION; INCIDENCE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 84873551869     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-011-0175-3     Document Type: Review

References (58)

1. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003; 349: 446-56.
2. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo Jr CA, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005; 16: 1115-25.
3. Weishaar RE, Kim SN, Saunders DE, Simpson RU. Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am J Physiol. 1990; 258: E134-42.
4. Weishaar RE, Simpson RU. Vitamin D3 and cardiovascular function in rats. J Clin Invest. 1987; 79: 1706-12.
5. Wu J, Garami M, Cheng T, Gardner DG. 1, 25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest. 1996; 97: 1577-88.
6. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002; 110: 229-38.
7. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005; 288: E125-32.
8. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1, 25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008; 74: 170-9.
9. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A. 2007; 104: 16810-5.
10. Woodhouse PR, Khaw KT, Plummer M, Foley A, Meade TW: Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet. 1994; 19; 343: 435-439.
11. Rostand SG. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension. 1997; 30: 150-6.
12. Kokot F, Pietrek J, Srokowska S, Wartenberg W, Kuska J, Jedrychowska M, et al. 25-hydroxyvitamin D in patients with essential hypertension. Clin Nephrol. 1981; 16: 188-92.
13. Sowers MR, Wallace RB, Lemke JH. The association of intakes of vitamin D and calcium with blood pressure among women. Am J Clin Nutr. 1985; 42: 135-42.
14. Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007; 167: 1159-65.
15. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens. 2007; 20: 713-9.
16. Judd SE, Nanes MS, Ziegler TR, Wilson PW, Tangpricha V. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third national health and nutrition examination survey. Am J Clin Nutr. 2008; 87: 136-41.
17. Hypponen E, Boucher BJ, Berry DJ, Power C. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. Diabetes. 2008; 57: 298-305.
18. Hintzpeter B, Mensink GB, Thierfelder W, Muller MJ, Scheidt-Nave C. Vitamin D status and health correlates among German adults. Eur J Clin Nutr. 2008; 62: 1079-89.
19. • Burgaz A, Byberg L, Rautiainen S, Orsini N, Hakansson N, Arnlov J, Sundstrom J, Lind L, Melhus H, Michaelsson K, Wolk A: Confirmed hypertension and plasma 25(OH)D concentrations amongst elderly men. J Intern Med 2011; 269: 211-218. In this study, investigators confirmed hypertension by both office and 24-hour blood pressure measurements.
20. Reis JP. von MD, Kritz-Silverstein D, Wingard DL, Barrett-Connor E: Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care. 2007; 30: 1549-55.
21. Rueda S, Fernandez-Fernandez C, Romero F, de Martinez OJ, Vidal J. Vitamin D, PTH, and the metabolic syndrome in severely obese subjects. Obes Surg. 2008; 18: 151-4.
22. Snijder MB, Lips P, Seidell JC, Visser M, Deeg DJ, Dekker JM, et al. Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. J Intern Med. 2007; 261: 558-65.
23. •• Wei MY, Giovannucci EL: Vitamin D and multiple health outcomes in the Harvard cohorts. Mol Nutr Food Res 2010; 54: 1114-1126. This review summarizes studies of vitamin D and cardiovascular endpoints in Harvard study cohorts.
24. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension. 2007; 49: 1063-9.
25. Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension. 2008; 52: 828-32.
26. Forman JP, Bischoff-Ferrari HA, Willett WC, Stampfer MJ, Curhan GC. Vitamin D intake and risk of incident hypertension: results from three large prospective cohort studies. Hypertension. 2005; 46: 676-82.
27. Wang L, Manson JE, Buring JE, Lee IM, Sesso HD. Dietary intake of dairy products, calcium, and vitamin D and the risk of hypertension in middle-aged and older women. Hypertension. 2008; 51: 1073-9.
28. •• Jorde R, Figenschau Y, Emaus N, Hutchinson M, Grimnes G: Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension. Hypertension. 2010; 55: 792-798. This study that confirms an association between vitamin D levels and prevalent hypertension, but investigators did not observe an association between vitamin D level and incident hypertension.
29. • Griffin FC, Gadegbeku CA, Sowers MR: Vitamin D and Subsequent Systolic Hypertension Among Women. Am J Hypertens. 2010. This prospective study found an association between single-time measure of vitamin D among young adult women with systolic hypertension at 14 years of follow-up.
30. • Burgaz A, Orsini N, Larsson SC, Wolk A: Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. J Hypertens. 2010. This comprehensive systematic review included four prospective studies and 14 cross-sectional studies. It concluded that blood 25-hydroxyvitamin D concentration is inversely associated with hypertension.
31. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003; 41: 105-12.
32. Zittermann A, Schleithoff SS, Koerfer R. Vitamin D insufficiency in congestive heart failure: why and what to do about it? Heart Fail Rev. 2006; 11: 25-33.
33. Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Addesso V, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. 1997; 103: 197-207.
34. Pilz S, Marz W, Wellnitz B, Seelhorst U, Fahrleitner-Pammer A, Dimai HP, et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab. 2008; 93: 3927-35.
35. Lind L, Wengle B, Ljunghall S. Blood pressure is lowered by vitamin D (alphacalcidol) during long-term treatment of patients with intermittent hypercalcaemia. A double-blind, placebo-controlled study. Acta Med Scand. 1987; 222: 423-7.
36. Lind L, Lithell H, Skarfors E, Wide L, Ljunghall S. Reduction of blood pressure by treatment with alphacalcidol. A double-blind, placebo-controlled study in subjects with impaired glucose tolerance. Acta Med Scand. 1988; 223: 211-7.
37. Zittermann A, Frisch S, Berthold HK, Gotting C, Kuhn J, Kleesiek K, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr. 2009; 89: 1321-7.
38. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med. 2008; 25: 320-5.
39. • Jorde R, Figenschau Y: Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. Eur J Nutr. 2009 Sep; 48(6): 349-54. This study was designed to study whether supplementation with vitamin D would improve glycemic control in patients with type 2 diabetes. The study did not demonstrate that vitamin D supplementation improves glucose metabolism in subjects with type 2 diabetes but without vitamin D deficiency.
40. Scragg R, Khaw KT, Murphy S. Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults. Eur J Clin Nutr. 1995; 49: 640-6.
41. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006; 83: 754-9.
42. Nagpal J, Pande JN, Bhartia A. A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med. 2009; 26: 19-27.
43. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. 2001; 86: 1633-7.
44. Major GC, Alarie F, Dore J, Phouttama S, Tremblay A. Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr. 2007; 85: 54-9.
45. • Margolis KL, Ray RM, Van HL, Manson JE, Allison MA, Black HR, Beresford SA, Connelly SA, Curb JD, Grimm RH, Jr., Kotchen TA, Kuller LH, Wassertheil-Smoller S, Thomson CA, Torner JC: Effect of calcium and vitamin D supplementation on blood pressure: the women's health initiative randomized trial. Hypertension. 2008; 52: 847-855.
46. Krause R, Buhring M, Hopfenmuller W, Holick MF, Sharma AM. Ultraviolet B and blood pressure. Lancet. 1998; 352: 709-10.
47. • Judd SE, Raiser SN, Kumari M, Tangpricha V: 1, 25-dihydroxyvitamin D3 reduces systolic blood pressure in hypertensive adults: a pilot feasibility study. J Steroid Biochem Mol Biol. 2010; 121: 445-447. This pilot study suggests that active vitamin D therapy is as effective as short-term intervention for improving hypertension.
48. Myrup B, Jensen GF, McNair P. Cardiovascular risk factors during estrogen-norethindrone and cholecalciferol treatment. Arch Intern Med. 1992; 152: 2265-8.
49. Pan WH, Wang CY, Li LA, Kao LS, Yeh SH. No significant effect of calcium and vitamin D supplementation on blood pressure and calcium metabolism in elderly Chinese. Chin J Physiol. 1993; 36: 85-94.
50. Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J Hypertens. 2009; 27: 1948-54.
51. •• Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, Lichtenstein AH, Lau J, Balk EM: Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010; 152: 307-314. This important meta-analysis concluded that the benefit of vitamin D supplementation on cardiometabolic outcomes is uncertain so far and emphasizes the need for future trials on this topic.
52. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010; 376: 1543-51.
53. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ. 2003; 326: 469.
54. Prince RL, Austin N, Devine A, Dick IM, Bruce D, Zhu K. Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Arch Intern Med. 2008; 168: 103-8.
55. Hsia J, Heiss G, Ren H, Allison M, Dolan NC, Greenland P, Heckbert SR, Johnson KC, Manson JE, Sidney S, Trevisan M: Calcium/vitamin D supplementation and cardiovascular events. Circulation. 2007,%20; 115: 846-854.
56. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis. 1999; 33: 73-81.
57. Kim HW, Park CW, Shin YS, Kim YS, Shin SJ, Kim YS, et al. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract. 2006; 102: c21-9.
58. •• Thadhani R, Appelbaum E, Chang Y, Pritchett Y, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson T, Audhya P, Andress D, Zhang W, Ye J, Packham D, Singh B, Zehnder D, Manning WJ, Pachika A, Solomon SD: Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease. Am J Nephrol. 2011; 33: 139-149. This international, multicenter, randomized controlled trial aims to investigate the effects of oral paricalcitol capsules on changes in cardiac structure and function in subjects with stage 3 or 4 chronic kidney disease who have left ventricular hypertrophy.